Merck KGaA, founded in 1668 in Darmstadt, Germany, is the world's oldest operating chemical and pharmaceutical company. The timeline traces its evolution from a small pharmacy to a global science and technology leader, highlighting key product innovations, strategic acquisitions, and corporate transformations.
Friedrich Jacob Merck acquires the Engel Pharmacy in Darmstadt, Germany, laying the cornerstone for what would become Merck KGaA. The company remains family-owned for centuries. #history #pharma
Heinrich Emanuel Merck begins large-scale production of morphine and other alkaloids, transitioning Merck from a pharmacy to a pharmaceutical manufacturer. This marks the birth of the modern pharmaceutical industry. #pharma #innovation
Merck issues its first catalog of chemical and pharmaceutical products, listing over 100 substances, establishing itself as a leading supplier to the scientific community. #pharma #history
Merck establishes a subsidiary in New York, initially importing and distributing German-made products. After World War I, this subsidiary becomes the independent company Merck & Co. in the US. #expansion #business
Merck introduces Veronal (barbital), the first barbiturate sedative, revolutionizing sleep medicine. It becomes a blockbuster drug. #pharma #medicine
Merck converts from a partnership to a publicly traded company (Kommanditgesellschaft auf Aktien), allowing wider ownership while the Merck family retains majority control. #finance #corporate
Merck chemists develop an industrial process for synthesizing vitamin C, enabling mass production for nutrition and pharmaceutical use. #chemistry #vitamins
Merck synthesizes dimethylbiguanide, later known as metformin, an oral diabetes drug. However, clinical development stalls until the 1990s. #pharma #diabetes
Merck establishes a dedicated central research laboratory in Darmstadt, focusing on pharmaceutical R&D, leading to numerous drug discoveries. #research #pharma
Merck introduces fenoterol, a β₂-agonist bronchodilator for asthma, under the brand name Berotec. It becomes an important rescue medication. #pharma #asthma
The company restructures to form E. Merck AG, unifying its pharmaceutical and chemical businesses under a corporate umbrella. #corporate #M&A
Merck begins producing liquid crystals for displays, a technological leap that positions Merck as a global leader in advanced materials for electronics. #LCD #technology
Merck establishes Merck Sharp & Dohme (MSD) as a joint venture with the US Merck & Co., but later regains full control of its international business. #expansion #business
Merck launches Glucophage (metformin) in France, which becomes a gold standard for type 2 diabetes treatment. The drug is later licensed to Bristol-Myers Squibb. #pharma #diabetes
Merck receives FDA approval for Zerit (stavudine), a nucleoside analog reverse transcriptase inhibitor for HIV/AIDS, contributing to early combination therapy. #pharma #HIV
The company restructures into a KGaA (partnership limited by shares), reinforcing family control and transparency. #corporate #finance
Merck expands its performance materials division by acquiring Sorbent Technologies, enhancing its expertise in chromatography and purification. #M&A #chemicals
Merck spins off its generic drug business to focus on innovation, forming a separate company, Merck Generics (later acquired by other firms). #corporate #pharma
Merck KGaA launches Erbitux (cetuximab), a monoclonal antibody for colorectal cancer and head-and-neck cancer, becoming a major oncology product. #pharma #oncology
Merck KGaA sells its US-based generics business to the American Merck & Co., finalizing the legal separation between the two entities. #M&A #business
Merck acquires Swiss biotech Serono for €10.6 billion, creating a global leader in fertility, neurology, and oncology. This is the largest acquisition in Merck's history. #M&A #biotech
Merck merges Serono with its existing pharma division to form Merck Serono, a dedicated biopharmaceutical arm. #corporate #pharma
Merck Serono's Rebif (interferon beta-1a) gains regulatory approval for relapsing multiple sclerosis, becoming a key revenue driver. #pharma #MS
Merck acquires Millipore Corporation for $6 billion, strengthening its life science tools and lab supplies business. #M&A #lifescience
Merck divests its European generics business to focus on innovative pharmaceuticals and life sciences. #corporate #pharma
Karl-Ludwig Kley becomes CEO, steering Merck through major transformation, emphasizing growth in healthcare, life sciences, and performance materials. #leadership #corporate
Merck acquires AZ Electronic Materials for $2.6 billion, expanding its specialty chemicals for semiconductors and displays. #M&A #chemicals
Merck announces the $17 billion acquisition of Sigma-Aldrich, a leading life science and chemical supplier, to dominate the lab supply market. #M&A #lifescience
Merck's Mavenclad (cladribine tablets) receives EU approval for relapsing multiple sclerosis, offering a novel oral treatment. #pharma #MS
The company rebrands as Merck KGaA, emphasizing its historical roots and updated corporate structure. External communication uses 'Merck' globally. #corporate #branding
Merck acquires Versum Materials for $5.9 billion, strengthening its semiconductor materials business. #M&A #semiconductors
Merck's anti-PD-L1 antibody Bavencio (avelumab) receives FDA approval for Merkel cell carcinoma and later for urothelial carcinoma. #pharma #immunotherapy
Merck participates in global COVID-19 efforts, developing antiviral candidates and collaborating on vaccine production. Its life science division supplies critical raw materials. #pandemic #pharma
Merck sells its consumer health division to Procter & Gamble for €3.4 billion, focusing on prescription pharmaceuticals and life sciences. #M&A #corporate
Merck acquires Exelead, a CDMO for complex injectables, boosting its contract development and manufacturing capabilities. #M&A #pharma
Merck's bispecific antibody Tepkinly (epcoritamab) receives accelerated FDA approval for relapsed/refractory B-cell lymphoma. #pharma #oncology
Merck and BioNTech collaborate to develop personalized mRNA cancer vaccines, leveraging Merck's manufacturing and commercial capabilities. #pharma #biotech